JP2006526592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526592A5 JP2006526592A5 JP2006508289A JP2006508289A JP2006526592A5 JP 2006526592 A5 JP2006526592 A5 JP 2006526592A5 JP 2006508289 A JP2006508289 A JP 2006508289A JP 2006508289 A JP2006508289 A JP 2006508289A JP 2006526592 A5 JP2006526592 A5 JP 2006526592A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- growth factor
- fibroblast growth
- plasmid
- hypercholesterolemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013612 plasmid Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 13
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 11
- 229940126864 fibroblast growth factor Drugs 0.000 claims 11
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 10
- 206010012601 diabetes mellitus Diseases 0.000 claims 10
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 210000004165 myocardium Anatomy 0.000 claims 8
- 210000002027 skeletal muscle Anatomy 0.000 claims 7
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 210000004204 blood vessel Anatomy 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 210000002565 arteriole Anatomy 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 230000002107 myocardial effect Effects 0.000 claims 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010069729 Collateral circulation Diseases 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 244000309466 calf Species 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 231100001055 skeletal defect Toxicity 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47595903P | 2003-06-05 | 2003-06-05 | |
| US56091504P | 2004-04-09 | 2004-04-09 | |
| US56619304P | 2004-04-28 | 2004-04-28 | |
| PCT/EP2004/006903 WO2004108167A1 (en) | 2003-06-05 | 2004-06-04 | Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006526592A JP2006526592A (ja) | 2006-11-24 |
| JP2006526592A5 true JP2006526592A5 (enExample) | 2007-05-17 |
Family
ID=33514717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508289A Pending JP2006526592A (ja) | 2003-06-05 | 2004-06-04 | 血管由来の欠損に関連する高コレステロール血症または糖尿病の治療のための、線維芽細胞成長因子をコードするプラスミド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050096286A1 (enExample) |
| EP (1) | EP1677831A1 (enExample) |
| JP (1) | JP2006526592A (enExample) |
| KR (1) | KR20060052692A (enExample) |
| AU (2) | AU2004244756A1 (enExample) |
| BR (1) | BRPI0410844A (enExample) |
| CA (1) | CA2526792A1 (enExample) |
| EA (1) | EA009390B1 (enExample) |
| NO (1) | NO20060032L (enExample) |
| NZ (1) | NZ543717A (enExample) |
| WO (1) | WO2004108167A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7038026B2 (en) | 2000-05-26 | 2006-05-02 | Centelion | Purification of a triple heli formation with an immobilized oligonucleotide |
| US7279313B2 (en) | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| FR2822476B1 (fr) | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
| EP1699819A2 (en) * | 2003-12-29 | 2006-09-13 | Centelion | Treatment of coronary or peripheral ischemia |
| AU2007212260A1 (en) * | 2006-02-09 | 2007-08-16 | Sangamo Therapeutics, Inc. | Method for treating peripheral arterial disease with zinc finger proteins |
| MX2012004303A (es) * | 2009-10-15 | 2012-06-25 | Genentech Inc | Factores de crecimiento de fibroblasto quimericos con especificacion de receptor alterada. |
| JP5767314B2 (ja) | 2010-04-16 | 2015-08-19 | ソーク インスティチュート フォー バイオロジカル スタディーズ | Ｆｇｆを用いて代謝障害を処置するための方法 |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| JP6621752B2 (ja) | 2013-10-21 | 2019-12-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法 |
| EP3368059A4 (en) | 2015-10-30 | 2019-03-27 | Salk Institute for Biological Studies | TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) -1 ANALOGUE |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| US11746352B2 (en) * | 2019-12-30 | 2023-09-05 | Eligo Bioscience | Microbiome modulation of a host by delivery of DNA payloads with minimized spread |
| US12098372B2 (en) | 2019-12-30 | 2024-09-24 | Eligo Bioscience | Microbiome modulation of a host by delivery of DNA payloads with minimized spread |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4692435A (en) * | 1978-11-06 | 1987-09-08 | Choay, S.A. | Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation |
| CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| IL72058A (en) * | 1984-06-08 | 1988-03-31 | Ram Lavie | Method for heat and mass exchange operations |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4686113A (en) * | 1985-12-18 | 1987-08-11 | Fairchild Semiconductor Corporation | Plasma confinement in a low pressure electrically grounded R.F. heated reactor and deposition method |
| US5827826A (en) * | 1986-03-03 | 1998-10-27 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compositions of human endothelial cell growth factor |
| ZA874487B (en) * | 1986-06-23 | 1987-12-23 | Merck & Co.,Inc. | Novel hmg-coa reductase inhibitors |
| CA1322163C (en) * | 1986-07-03 | 1993-09-14 | Kenneth A. Thomas, Jr. | Plasminogen activator production |
| US5045565A (en) * | 1987-03-09 | 1991-09-03 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
| US4965200A (en) * | 1989-06-23 | 1990-10-23 | Merck & Co., Inc. | Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs |
| FR2663639B1 (fr) * | 1990-06-26 | 1994-03-18 | Rhone Poulenc Sante | Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation. |
| US5733871A (en) * | 1991-11-08 | 1998-03-31 | The General Hospital Corporation | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
| US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
| WO1999001150A1 (en) * | 1997-07-03 | 1999-01-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for treating, preventing and/or delaying ischemic cell death |
| DE69838526T2 (de) * | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Gerät zum Freisetzen eines Medikaments im Herzen |
| US20020122792A1 (en) * | 1998-07-24 | 2002-09-05 | Thomas J. Stegmann | Induction of neoangiogenesis in ischemic myocardium |
| US6642026B2 (en) * | 2000-08-15 | 2003-11-04 | Phage Biotechnology Corporation | Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| US6102887A (en) * | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
| US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
| US20020037508A1 (en) * | 2000-01-19 | 2002-03-28 | Michele Cargill | Human single nucleotide polymorphisms |
| US6988004B2 (en) * | 2000-05-16 | 2006-01-17 | Bioheart, Inc. | Method for inducing angiogenesis by electrical stimulation of muscles |
| WO2002046220A2 (en) * | 2000-12-07 | 2002-06-13 | Gencell S.A. | Sequences upstream of the carp gene, vectors containing them and uses thereof |
-
2004
- 2004-06-04 BR BRPI0410844-2A patent/BRPI0410844A/pt not_active IP Right Cessation
- 2004-06-04 JP JP2006508289A patent/JP2006526592A/ja active Pending
- 2004-06-04 EP EP04740314A patent/EP1677831A1/en not_active Withdrawn
- 2004-06-04 CA CA002526792A patent/CA2526792A1/en not_active Abandoned
- 2004-06-04 NZ NZ543717A patent/NZ543717A/en unknown
- 2004-06-04 AU AU2004244756A patent/AU2004244756A1/en not_active Abandoned
- 2004-06-04 WO PCT/EP2004/006903 patent/WO2004108167A1/en not_active Ceased
- 2004-06-04 EA EA200501846A patent/EA009390B1/ru not_active IP Right Cessation
- 2004-06-04 KR KR1020057023058A patent/KR20060052692A/ko not_active Ceased
- 2004-06-07 US US10/861,906 patent/US20050096286A1/en not_active Abandoned
-
2006
- 2006-01-04 NO NO20060032A patent/NO20060032L/no not_active Application Discontinuation
-
2010
- 2010-12-22 AU AU2010257389A patent/AU2010257389A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hughes et al. | Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF | |
| Kim et al. | The enhancement of mature vessel formation and cardiac function in infarcted hearts using dual growth factor delivery with self-assembling peptides | |
| Hariawala et al. | VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts | |
| Lopez et al. | Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia | |
| JP2006526592A5 (enExample) | ||
| JP2020117546A (ja) | 脈管形成因子の用量および心筋血流を改善するための投与方法 | |
| Nakajima et al. | Therapeutic angiogenesis by the controlled release of basic fibroblast growth factor for ischemic limb and heart injury: toward safety and minimal invasiveness | |
| JP2010523264A5 (enExample) | ||
| JP2017002083A5 (enExample) | ||
| JP2004337400A (ja) | 薬剤投与キット | |
| JP2003519097A5 (enExample) | ||
| JP2019081805A (ja) | 再狭窄の予防または治療のための化合物および方法 | |
| JP2010163457A (ja) | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 | |
| US20030139333A1 (en) | Methods and compositions for promoting angiogenesis | |
| AU772857B2 (en) | Method of inducing angiogenesis | |
| JP2003513942A5 (enExample) | ||
| Cao et al. | Functional recovery of myocardial infarction by specific EBP‐PR1P peptides bridging injectable cardiac extracellular matrix and vascular endothelial growth factor | |
| JP2007501282A (ja) | 哺乳類の四肢の細胞へのポリヌクレオチドの静脈内送達 | |
| KR20060052692A (ko) | 고콜레스테롤혈증 또는 당뇨병과 관련된 혈관형성 결함을치료하기 위한 섬유모세포 성장 인자를 코딩하는플라스미드 | |
| Matloff et al. | Hemodynamic effects of glucagon and intraaortic balloon counterpulsation in canine myocardial infarction | |
| Li et al. | Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow | |
| Liang et al. | Effects of salidroside on myocardial ischemia/reperfusion injury in rats | |
| Staudacher et al. | Cellular and molecular therapeutic modalities for arterial obstructive syndromes | |
| Bashir et al. | Angiogenic gene therapy: pre-clinical studies and phase I clinical data | |
| Khan et al. | Therapeutic angiogenesis for coronary artery disease |